Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19 CAR-T Therapy for Relapsed/Refractory Autoimmune Diseases
NCT07193667Recruiting
- Start
- Oct 2025
- Primary completion
- Sep 2027
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Open-label, single-arm trial of CD19 CAR-T cells in systemic lupus erythematosus (SLE), systemic sclerosis (SSc), inflammatory myopathy (IIM) and 1 more. Primary endpoint: chimeric status at 1 year. Started Oct 2025; status: recruiting.
02
Drugs
CD19 CAR-T cells
03
Conditions
systemic lupus erythematosus (SLE)systemic sclerosis (SSc)inflammatory myopathy (IIM)immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT07193667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07193667.